Novo Nordisk (NVO) has received the recommendation of the European Medicines Agency's Committee for Medicinal Products for Human Use for the extension of the current indication for Saxenda, according to a Friday statement from the regulator.
The update in Saxenda's marketing authorization, once approved, will include the treatment of children aged 6 years to less than 12 years, the EMA said.
Saxenda is currently indicated as an "adjunct to healthy nutrition and increased physical activity for weight management," according to the statement.
Price: 67.52, Change: -0.65, Percent Change: -0.95
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。